Transcend Therapeutics: Funding, Investors & Team (Oct 2026)
Transcend Therapeutics is a neuroscience-focused firm that is in the trial stages of developing the next generation of psychoactive medications for neuropsychiatric disorder. Transcend creates drugs that are affordable for a larger proportion of sick patients, including the tens of millions of people who already take psychotropic drugs. We have real-world data demonstrating that >85% of patients with PTSD and depression significantly benefited from our primary product. With ambitions to extend into depression and other indications, we have already pushed our lead chemical into a PTSD-specific Phase II research that has been approved.
Transcend Therapeutics has raised $40.0M across 1 funding round on record, the most recent a Series A of $40.0M announced in Feb 2023.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Transcend Therapeutics Company Profile and Key Stats
Latest funding round on record: Feb 2023.
Transcend Therapeutics Funding Rounds
Transcend Therapeutics Founders and Leadership Team
Contact details for the Transcend Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Transcend Therapeutics Funding Compared to Other Biotechnology Startups
Transcend Therapeutics' latest round of $40.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Transcend Therapeutics in Biotechnology and Waltham
Companies Similar to Transcend Therapeutics
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Transcend Therapeutics Funding FAQs
What does Transcend Therapeutics do?
Transcend Therapeutics is a neuroscience-focused firm that is in the trial stages of developing the next generation of psychoactive medications for neuropsychiatric disorder. Transcend creates drugs that are affordable for a larger proportion of sick patients, including the tens of millions of people who already take psychotropic drugs. We have real-world data demonstrating that >85% of patients with PTSD and depression significantly benefited from our primary product. With ambitions to extend into depression and other indications, we have already pushed our lead chemical into a PTSD-specific Phase II research that has been approved.
How much funding has Transcend Therapeutics raised?
Transcend Therapeutics has raised $40.0M across 1 round on record. The most recent is a Series A of $40.0M announced in Feb 2023.
When did Transcend Therapeutics last raise funding?
Transcend Therapeutics' most recent funding round on record is a Series A of $40.0M, announced in Feb 2023.
Who is the CEO of Transcend Therapeutics?
Blake Mandell is listed as CEO at Transcend Therapeutics.
Where is Transcend Therapeutics headquartered?
Transcend Therapeutics is based in Waltham, Massachusetts, United States.
How many employees does Transcend Therapeutics have?
Transcend Therapeutics is in the 1-10 employee band.
How does Transcend Therapeutics' funding compare to other Biotechnology startups?
Transcend Therapeutics' latest round of $40.0M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Transcend Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Transcend Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.